『Prescription for Better Access』のカバーアート

Prescription for Better Access

Prescription for Better Access

著者： Mark Hansan and Dr. Scott Howell
無料で聴く

このコンテンツについて

 With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.© 2025 Prescription for Better Access Mark Hansan and Dr. Scott Howell 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Charting a Path Forward for More Patient-Centered Value Assessment Methods

    Charting a Path Forward for More Patient-Centered Value Assessment Methods
    2025/10/17

    In this episode, we talk with Richard Xie, Senior Health Economist at RA Capital, and Gunnar Esiason, Senior Director of Patient Engagement at Raven (RA Capital Ventures), about value frameworks in pharma. We unpack how Generalized Cost-Effectiveness Analysis (GCEA) builds on traditional Cost-Effectiveness Analysis (CEA) and differs from ICER’s model. The conversation explores what these approaches mean for pricing, access, and patient voice—especially in rare and high-innovation settings.

    Through the Cidara CD388 flu drug case, we discuss how assumptions shape value and trade-offs from manufacturer and patient perspectives. The episode highlights how evidence, incentives, and outcomes align—or conflict—in today’s system, and what reforms could better connect value frameworks to affordability and equitable access.

    • Richard Xie, Senior Health Economist, RA Capital Management
    • Gunnar Esiason, MBA, MPH, Senior Director, Head of Patient Engagement and Patient-Centered Innovation, Raven (RA Capital Ventures)
    • Patient-Centered Value Assessment Models
    • Episode 26: Sarah Emond, ICER
    • Peter Kolchinski, The Great American Drug Deal
    • NICE (UK)
    • CDA (Canada)
    • Australia CHAP
    • Trikafta
    • ICER Report on Cystic Fibrosis
    • No Patient Left Behind
    • GCEA Calculator
    • Boomer Esiason Foundation
    • Aurora Biosciences
    • Most-Favored-Nation Drug Pricing Order

    Questions or comments? Email comments@prescriptionforbetteraccess.com.

    Follow us on X, LinkedIn, YouTube, and Threads.
    続きを読む 一部表示
    1分未満
  • IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO

    IRA, Part D Redesign & the Future of Drug Access: A Conversation with Jon Blum, Former CMS Principal Deputy Administrator and COO
    2025/09/18
    In this episode, former CMS official Jon Blum reflects on the evolution and impact of the IRA’s drug provisions—from foundational drivers and political trade-offs to how 2026 Part D redesign and the M3P cost-smoothing program are reshaping access. We explore why M3P adoption remains limited, how CMS is monitoring plan behavior around negotiated pricing, and what shrinking standalone Part D options may mean for patients, especially in rural areas. Jon also challenges the “blame game” in Washington—emphasizing the systemic incentives behind each actor—and shares his own prescription for equitably balancing drug affordability, innovation, and policy integrity, including thoughts on MFN and future reform paths.
    続きを読む 一部表示
    1分未満
  • The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference

    The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference
    2025/07/17

    At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.

    • Conference Overview
    • Sarah Emond – ICER
    • John O’Brien – National Pharmaceutical Council
    • Annette Powers – Bristol Myers Squibb
    • Ray Pressburger – Accenture
    • Stuart Altman – Power, Politics and Universal Health Care
    • PBMs
    • 340B Program
    • Copay Maximizers
    • Net Price
    • Lilly Direct
    • Indolent Disease, PFS
    • Concomitant Drug
    • HIV & AZT
    • Orphan Drugs
    • Calquence vs Imbruvica
    • Value-Based Contracts
    • Outcome-Based Contracts
    • Disruptive PBMs
    • CostPlus Drugs
    • Fair Access 2024
    • Drug Rebates
    • Drug Carve-Outs
    • Dynamic Pricing
    • Accelerated Approvals
    • ICER Assessment

    Questions? Email comments@prescriptionforbetteraccess.com.
    Follow us on X, LinkedIn, YouTube, and Threads.
    続きを読む 一部表示
    1分未満
まだレビューはありません